SUO 2024: Efficacy and Safety of Padeliporfin VTP for Treatment of Low-Grade UTUC: ENLIGHTED Phase 3 study SUO 2024: Voided Urine Cell-Free DNA as a Biomarker for Upper Tract Urothelial Carcinoma SUO ...

Bladder cancer is one of the most common cancers in the United States, impacting approximately 83,000 Americans each year. It is a disease that shocks not only the individuals diagnosed but also their ...

In Barcelona this past September, we witnessed another major milestone in the rapid development of bladder cancer therapeutics. The practice changing data of the phase III NIAGARA trial showed that ...

The IBCN 2024 occurred in Bern, Switzerland, from September 19th to September 21st, 2024. The event featured a keynote lecture on Friday morning by Niko Beerenwinkel, Professor of Computational ...

(UroToday.com) The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Brian Shuch discussing results from ZIRCON, a phase 3 ...

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10 th and 13 th, 2023 was host to a game changing session. Professor Peter Mulders ...

Background: With limitations of conventional imaging and biopsy, accurate, non-invasive techniques to detect clear-cell renal cell carcinoma in patients with renal masses remain an unmet need.

Current epidemiological indicators reflect the prevalence of prostate-specific antigen (PSA) testing rather than the actual incidence of clinically significant prostate cancer. These indicators are ...

Tubulocystic renal cell carcinoma (TC-RCC) is uncommon and is defined by exclusive tubulocystic growth. Its clinicopathology is still evolving. Twenty-eight cases of so-defined TC-RCC were studied for ...

Utilization of neoadjuvant systemic therapy (NAT) prior to radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) is inconsistent, and optimal patient selection for NAT is ...

We sought to compare our results of patients treated with Cs-131 prostate brachytherapy (PB) as monotherapy to recently published results of patients treated with stereotactic body radiotherapy. We ...

Background An accurate method of assessing the response of muscle-invasive bladder cancer (MIBC) to neoadjuvant treatment is needed for selecting candidates for bladder-sparing strategies. Purpose To ...